Kausik K Ray1, Stephen J Nicholls2, Kevin A Buhr3, Henry N Ginsberg4, Jan O Johansson5, Kamyar Kalantar-Zadeh6, Ewelina Kulikowski5, Peter P Toth7, Norman Wong5, Michael Sweeney5, Gregory G Schwartz8. 1. Imperial Centre for Cardiovascular Disease Prevention, Imperial College London, United Kingdom. 2. Monash Cardiovascular Research Centre, Monash University, Melbourne, Victoria, Australia. 3. Statistical Data Analysis Center, University of Wisconsin-Madison. 4. Irving Institute for Clinical and Translational Research, Columbia University, New York, New York. 5. Resverlogix Corporation, Calgary, Alberta, Canada. 6. Division of Nephrology and Hypertension, University of California-Irvine. 7. CGH Medical Center, Sterling, Illinois, and Cicarrone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University School of Medicine, Baltimore, Maryland. 8. Division of Cardiology, University of Colorado School of Medicine, Aurora.
Abstract
Importance: Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest favorable effects on clinical outcomes. Objective: To test whether apabetalone significantly reduces major adverse cardiovascular events. Design, Setting, and Participants: A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019. Interventions: Patients were randomized (1:1) to receive apabetalone, 100 mg orally twice daily (n = 1215), or matching placebo (n = 1210) in addition to standard care. Main Outcomes and Measures: The primary outcome was a composite of time to the first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Results: Among 2425 patients who were randomized (mean age, 62 years; 618 women [25.6%]), 2320 (95.7%) had full ascertainment of the primary outcome. During a median follow-up of 26.5 months, 274 primary end points occurred: 125 (10.3%) in apabetalone-treated patients and 149 (12.4%) in placebo-treated patients (hazard ratio, 0.82 [95% CI, 0.65-1.04]; P = .11). More patients allocated to apabetalone than placebo discontinued study drug (114 [9.4%] vs 69 [5.7%]) for reasons including elevations of liver enzyme levels (35 [2.9%] vs 11 [0.9%]). Conclusions and Relevance: Among patients with recent acute coronary syndrome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selective bromodomain and extraterminal protein inhibitor apabetalone added to standard therapy did not significantly reduce the risk of major adverse cardiovascular events. Trial Registration: ClinicalTrials.gov Identifier: NCT02586155.
RCT Entities:
Importance: Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest favorable effects on clinical outcomes. Objective: To test whether apabetalone significantly reduces major adverse cardiovascular events. Design, Setting, and Participants: A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019. Interventions: Patients were randomized (1:1) to receive apabetalone, 100 mg orally twice daily (n = 1215), or matching placebo (n = 1210) in addition to standard care. Main Outcomes and Measures: The primary outcome was a composite of time to the first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke. Results: Among 2425 patients who were randomized (mean age, 62 years; 618 women [25.6%]), 2320 (95.7%) had full ascertainment of the primary outcome. During a median follow-up of 26.5 months, 274 primary end points occurred: 125 (10.3%) in apabetalone-treated patients and 149 (12.4%) in placebo-treated patients (hazard ratio, 0.82 [95% CI, 0.65-1.04]; P = .11). More patients allocated to apabetalone than placebo discontinued study drug (114 [9.4%] vs 69 [5.7%]) for reasons including elevations of liver enzyme levels (35 [2.9%] vs 11 [0.9%]). Conclusions and Relevance: Among patients with recent acute coronary syndrome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selective bromodomain and extraterminal protein inhibitor apabetalone added to standard therapy did not significantly reduce the risk of major adverse cardiovascular events. Trial Registration: ClinicalTrials.gov Identifier: NCT02586155.
Authors: Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi Journal: N Engl J Med Date: 2015-09-17 Impact factor: 91.245
Authors: Daisuke Shishikura; Yu Kataoka; Satoshi Honda; Kohei Takata; Susan W Kim; Jordan Andrews; Peter J Psaltis; Michael Sweeney; Ewelina Kulikowski; Jan Johansson; Norman C W Wong; Stephen J Nicholls Journal: Am J Cardiovasc Drugs Date: 2019-02 Impact factor: 3.571
Authors: Stephen J Nicholls; Allan Gordon; Jan Johansson; Kathy Wolski; Christie M Ballantyne; John J P Kastelein; Allen Taylor; Marilyn Borgman; Steven E Nissen Journal: J Am Coll Cardiol Date: 2011-01-20 Impact factor: 24.094
Authors: Kausik K Ray; Helen M Colhoun; Michael Szarek; Marie Baccara-Dinet; Deepak L Bhatt; Vera A Bittner; Andrzej J Budaj; Rafael Diaz; Shaun G Goodman; Corinne Hanotin; Robert A Harrington; J Wouter Jukema; Virginie Loizeau; Renato D Lopes; Angèle Moryusef; Jan Murin; Robert Pordy; Arsen D Ristic; Matthew T Roe; José Tuñón; Harvey D White; Andreas M Zeiher; Gregory G Schwartz; Philippe Gabriel Steg Journal: Lancet Diabetes Endocrinol Date: 2019-07-01 Impact factor: 32.069
Authors: Ravi Jahagirdar; Haiyan Zhang; Salman Azhar; Jennifer Tobin; Sarah Attwell; Raymond Yu; Jin Wu; Kevin G McLure; Henrik C Hansen; Gregory S Wagner; Peter R Young; Rai Ajit K Srivastava; Norman C W Wong; Jan Johansson Journal: Atherosclerosis Date: 2014-06-28 Impact factor: 5.162
Authors: Stephen J Nicholls; Kausik K Ray; Jan O Johansson; Alan Gordon; Michael Sweeney; Chris Halliday; Ewelina Kulikowski; Norman Wong; Susan W Kim; Gregory G Schwartz Journal: Am J Cardiovasc Drugs Date: 2018-04 Impact factor: 3.571
Authors: Laura M Tsujikawa; Li Fu; Shovon Das; Christopher Halliday; Brooke D Rakai; Stephanie C Stotz; Christopher D Sarsons; Dean Gilham; Emily Daze; Sylwia Wasiak; Deborah Studer; Kristina D Rinker; Michael Sweeney; Jan O Johansson; Norman C W Wong; Ewelina Kulikowski Journal: Clin Epigenetics Date: 2019-07-12 Impact factor: 6.551
Authors: Steven P Marso; Gilbert H Daniels; Kirstine Brown-Frandsen; Peter Kristensen; Johannes F E Mann; Michael A Nauck; Steven E Nissen; Stuart Pocock; Neil R Poulter; Lasse S Ravn; William M Steinberg; Mette Stockner; Bernard Zinman; Richard M Bergenstal; John B Buse Journal: N Engl J Med Date: 2016-06-13 Impact factor: 176.079
Authors: Luca Liberale; Lina Badimon; Fabrizio Montecucco; Thomas F Lüscher; Peter Libby; Giovanni G Camici Journal: J Am Coll Cardiol Date: 2022-03-01 Impact factor: 24.094
Authors: Maciej Banach; Paweł Burchardt; Krzysztof Chlebus; Piotr Dobrowolski; Dariusz Dudek; Krzysztof Dyrbuś; Mariusz Gąsior; Piotr Jankowski; Jacek Jóźwiak; Longina Kłosiewicz-Latoszek; Irina Kowalska; Maciej Małecki; Aleksander Prejbisz; Michał Rakowski; Jacek Rysz; Bogdan Solnica; Dariusz Sitkiewicz; Grażyna Sygitowicz; Grażyna Sypniewska; Tomasz Tomasik; Adam Windak; Dorota Zozulińska-Ziółkiewicz; Barbara Cybulska Journal: Arch Med Sci Date: 2021-11-08 Impact factor: 3.318
Authors: Kamyar Kalantar-Zadeh; Gregory G Schwartz; Stephen J Nicholls; Kevin A Buhr; Henry N Ginsberg; Jan O Johansson; Ewelina Kulikowski; Kenneth Lebioda; Peter P Toth; Norman Wong; Michael Sweeney; Kausik K Ray Journal: Clin J Am Soc Nephrol Date: 2021-04-27 Impact factor: 8.237
Authors: Arun Padmanabhan; Michael Alexanian; Ricardo Linares-Saldana; Rajan Jain; Deepak Srivastava; Bárbara González-Terán; Gaia Andreoletti; Yu Huang; Andrew J Connolly; Wonho Kim; Austin Hsu; Qiming Duan; Sarah A B Winchester; Franco Felix; Juan A Perez-Bermejo; Qiaohong Wang; Li Li; Parisha P Shah; Saptarsi M Haldar Journal: Circulation Date: 2020-10-23 Impact factor: 29.690